- Conditions
- Chronic Hepatitis C
- Interventions
- Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Brisbane, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 80,955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Carcinoma, Breast Cancer Female
- Interventions
- Breast Cancer Survivor Education Program
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 22 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Covid19, SARS-CoV-2 Infection
- Interventions
- GC4419, Placebo
- Drug
- Lead sponsor
- Galera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • St Louis, Missouri
- Conditions
- Meningococcal Vaccine
- Interventions
- Awareness, Education, Empowerment, Accessibility
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 16 Years to 99 Years
- Enrollment
- 1,326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Gainesville, Florida
- Conditions
- Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
- Interventions
- Educational Intervention, Questionnaire Administration, Survey Administration, Video
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemiparesis, Stroke
- Interventions
- Citizen Science intervention using kinect
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Amyloidosis
- Interventions
- Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- ixabepilone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Rectal Cancer
- Interventions
- Intraoperative Mobile Gamma Camera imaging, Endoscopic injection of 99mTc-sulfur colloid, Endoscopic injections of Spot, Preoperative flexible sigmoidoscopy, SPECT/CT
- Other · Drug · Procedure + 1 more
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Ovarian Cancer, Nonsmall Cell Lung Cancer
- Interventions
- XMT-1592
- Biological
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Graft Versus Host Disease
- Interventions
- Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Coronary Heart Disease
- Interventions
- MPSK3169A, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 34
- States / cities
- Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Masitinib, Imatinib
- Drug
- Lead sponsor
- AB Science
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Group Lifestyle Program, Usual Care
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Interventions
- TPI 287
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 6
- States / cities
- San Diego, California • Orlando, Florida • St Louis, Missouri + 3 more
- Conditions
- Molluscum Contagiosum
- Interventions
- VBP-245 Topical Gel, Vehicle
- Drug
- Lead sponsor
- Veloce BioPharma LLC
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Fort Washington, Pennsylvania • Greenville, South Carolina • Mt. Pleasant, South Carolina
- Conditions
- Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
- Interventions
- lenalidomide, prednisone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- ATN-224
- Drug
- Lead sponsor
- Attenuon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 6
- States / cities
- San Francisco, California • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Male Infertility, Nonobstructive Azoospermia, Azoospermia
- Interventions
- Platelet rich plasma
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Decitabine, Rapamycin
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
- Interventions
- GW679769
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 11
- States / cities
- San Francisco, California • Melbourne, Florida • West Palm Beach, Florida + 8 more
- Conditions
- Anxiety State
- Interventions
- Augmented Reality, Standard of Care preoperative teaching and handouts
- Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland